SLRX:NSD-Salarius Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.72

Change

+0.04 (+5.88)%

Market Cap

N/A

Volume

0.05M

Analyst Target

USD 4.43
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+4.66 (+0.94%)

USD 126.52B
REGN Regeneron Pharmaceuticals Inc

-13.15 (-2.30%)

USD 69.68B
ARGX argenx NV ADR

-1.02 (-0.17%)

USD 35.43B
ALNY Alnylam Pharmaceuticals Inc

-9.08 (-3.78%)

USD 30.51B
ONC BeiGene, Ltd.

-3.91 (-1.61%)

USD 26.35B
RPRX Royalty Pharma Plc

+0.16 (+0.50%)

USD 19.31B
SMMT Summit Therapeutics PLC

-1.51 (-5.78%)

USD 14.57B
INSM Insmed Inc

+0.04 (+0.06%)

USD 12.52B
INCY Incyte Corporation

-0.76 (-1.28%)

USD 11.72B
BMRN Biomarin Pharmaceutical Inc

+0.35 (+0.59%)

USD 11.50B

ETFs Containing SLRX

REM iShares Mortgage Real Est.. 2.86 % 0.48 %

+0.10 (+0.51%)

USD 0.68B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -60.87% 14% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -60.87% 14% F 8% B-
Trailing 12 Months  
Capital Gain -82.00% 18% F 7% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -82.00% 18% F 7% C-
Trailing 5 Years  
Capital Gain -99.44% 7% C- 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.44% 7% C- 2% F
Average Annual (5 Year Horizon)  
Capital Gain 96.04% 85% B 93% A
Dividend Return 96.04% 85% B 93% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 893.21% 12% F 5% F
Risk Adjusted Return 10.75% 63% D 45% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.